Vizamyl

INTRODUCTION Since the approval of three 18F labeled β-amyloid-targeting PET imaging agents, Amyvid (florbetapir f18, AV-45… Expand

In vivo imaging of fibrillar β-amyloid deposits may assist clinical diagnosis of Alzheimer’s disease (AD), aid treatment… Expand

Medicare’s decision to restrict coverage of florbetapir, a diagnostic agent for Alzheimer’s disease, exemplifies an inconsistent… Expand

In Alzheimer’s disease (AD), the deposition of β-amyloid (Aβ) is hypothesized to result in a series of secondary… Expand

The application of microfluidics to the synthesis of Positron Emission Tomography (PET) tracers has been explored for more than a… Expand

2013年10月25日，美国食品药品监督管理局（FDA）批准由GE Healthcare Ltd的分公司Medi—Physics生产的放射性诊断药物[18F]flutemetamol注射液（Vizamyl）在美国上市。 

Therapies targeting amyloid-β peptide currently represent approximately 50% of drugs now being developed for Alzheimer’s disease… Expand

Therapies targeting amyloid-β peptide currently represent approximately 50% of drugs now being developed for Alzheimer's disease… Expand

Physicians in the US who want to see how much amyloid-beta protein has accumulated in the brains of their patients with Alzheimer… Expand

There has been tremendous excitement regarding biomarkers that provide in vivo information on neurodegenerative diseases. Until… Expand